


Polymyxin B vials



Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against almost all gram-negative bacteria except the Proteus group.

Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible strains such as *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Escherichia coli*, *Aerobacter aerogenes or Klebsiella pneumoniae*.

Application: Administered systemically as intravenous infusions, intramuscular or intrathecal injections and locally as eye drops or subconjunctival injections.

Dosage form	Lyophilized vials
Strength	50000 units/vial
Compliance	USP
Manufacturing site	CMO for Xellia Pharmaceuticals ApS
Release site	CMO for Xellia Pharmaceuticals ApS
Site registered	US FDA
	Other health authorities
Regulatory	US dossier
documentation	RoW* dossier
Batch size	65000 vials
Packaging sizes	1 vial/pack
	10 vials/pack
	25 vials/pack
Shelf-life	24 months
Storage conditions	Between 15-25 °C (59-77°F)

*Rest of the World

Polymyxin B vial has a boxed warning for use by intrathecal or intramuscular route of administration, where patients must be hospitalized and under constant supervision by physician. In addition, there is risk of nephrotoxicity and neurotoxicity. The safety data on usage in pregnancy is lacking. For full prescribing information, including boxed warning, please visit: https://www.xellia.com/us/products/Polymyxin%20B%20for%20Injection,%20USP